Prostate Cancer - Results from #240

AlphaBet: Combination of Radium-223 and [17 7Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol). December 7, 2022

Evolving imaging methods of prostate cancer and the emergence of magnetic resonance imaging guided ablation techniques. December 7, 2022

The LINC00852/miR-29a-3p/JARID2 axis regulates the proliferation and invasion of prostate cancer cell. December 7, 2022

FDA Approval Summary: lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer. December 7, 2022

Non-specific PSMA-1007 bone uptake evaluated through PSMA-11 PET, bone scan and MRI triple validation in patients with biochemical recurrence of prostate cancer. December 7, 2022

Accuracy of Prostate Cancer Screening Recommendations for High-Risk Populations on YouTube and TikTok December 6, 2022

The Prostate Cancer Foundation Announces Inaugural $30 Million TACTICAL Awards Program for Innovative Prostate Cancer Research December 6, 2022

Prostate magnetic resonance imaging-targeted biopsy global grade correlates better than highest grade with prostatectomy grade. December 6, 2022

The diagnostic performance in clinically significant prostate cancer with PI-RADS version 2.1: simplified bpMRI versus standard mpMRI. December 6, 2022

The impact of locoregional treatments for metastatic castration resistant prostate cancer on disease progression: real life experience from a multicenter cohort. December 6, 2022

Magnetic Resonance-Guided Adaptive Radiotherapy for Prostate Cancer: The First Results from the MOMENTUM study, an International Registry for the Evidence-Based Introduction of Magnetic Resonance-Guided Adaptive Radiotherapy. December 6, 2022

Prostate cancer screening with prostate-specific antigen (PSA) to men over 70 years old in an urban health zone, 2018-2020: A cross-sectional study. December 6, 2022

Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer: A Randomized Clinical Trial. December 6, 2022

Leading National Prostate Cancer Nonprofit Spearheads Influential HHS Moonshot Meeting December 5, 2022

Novartis Pluvicto™ Shows Statistically Significant and Clinically Meaningful Radiographic Progression-Free Survival Benefit in Patients with PSMA–positive Metastatic Castration-Resistant Prostate Cancer December 5, 2022

Post-diagnostic Zinc Supplement Use and Prostate Cancer Survival Among Men With Nonmetastatic Prostate Cancer. December 5, 2022

Ethnic differences in prostate-specific antigen levels in men without prostate cancer: a systematic review. December 5, 2022

Extensive androgen receptor enhancer heterogeneity in primary prostate cancers underlies transcriptional diversity and metastatic potential. December 5, 2022

From Concept to Regulatory Drug Approval: Lessons for Theranostics. December 5, 2022

Oligometastatic Hormone-Sensitive Prostate Cancer. Why Radiotherapy? December 5, 2022

Page 13 of 1276

email news signup